TP53 and intrahepatic cholangiocarcinoma: The IPSS‐M model has shown an adjusted hazard ratio (HR) of 3.27 (the highest of all) for multihit TP53 aberration; the ELN 2022 classification now includes a new category termed “AML with mutated TP53” for patients with TP53 variant allele frequency (VAF) ≥ 10%; and the 2022 ICC has designated a unique category for MDS and AML with TP53 mutation at the height of the myeloid neoplasm classification hierarchy.